Published • loading... • Updated
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
The candidate produced 12.6% placebo-adjusted mean weight loss after 7 days in a head-to-head study with orforglipron, the company said.
- On Friday, Ambrosia Biosciences Inc. announced preclinical data for its development candidate AMB-702 during a poster presentation at the American Diabetes Association's 86th Scientific Sessions.
- In a head-to-head comparison, AMB-702 achieved placebo-adjusted mean weight loss of 12.6% after 7 days of daily dosing at 2 mg/kg, compared to 5.4% for a comparator at the same dose.
- Patrice Lee, President, cited "superior target coverage over 24 hours" as a key finding, noting that AMB-702 also improved glycemic control and enhanced insulin secretion in mouse models.
- Nick Traggis, CEO of Ambrosia, said the company looks forward to "advancing AMB-702 into the clinic early next year" to expand access to cardiometabolic therapies.
- Beyond AMB-702, the company's pipeline includes a once-weekly GLP-1 receptor agonist, a GIP receptor antagonist, and an amylin receptor agonist, enabling significant opportunities for combination therapies.
Insights by Ground AI
24 Articles
24 Articles
Coverage Details
Total News Sources24
Leaning Left2Leaning Right1Center14Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
12%
C 82%
Factuality
To view factuality data please Upgrade to Premium
